OBJECTIVE:
The American College of Cardiology/American Heart Association (ACA/AHA) recently revised their definitions of hypertension (HTN) with the addition of stage 1 HTN (either systolic (SBP) 130-139 or diastolic (DBP) 80-89 mmHg). Because the implications of this new definition in pregnancy are not known, we aimed to determine the frequency of adverse maternal and neonatal outcomes in stage 1 HTN at the last clinic visit before delivery. STUDY DESIGN: Secondary analysis of a multicenter randomized trial of antioxidants to prevent preeclampsia (PE) in singleton nulliparous low-risk women. BP was measured by trained staff and outcomes were adjudicated. For this analysis, we included women who delivered 36 weeks gestation and abstracted their most recent BP in clinic, within 30 days prior to delivery. The higher of systolic (SBP) and diastolic (DBP) was used for classification into: Group 1, those who were never diagnosed with pregnancy associated hypertension (PAH, defined as either SBP >140 or DBP >90 mmHg on two occasions at least 4 hours apart) and their last clinic BP was <130/80 mmHg; Group 2, women without PAH but last clinic BP was consistent with stage 1 HTN by the new classification; and Group 3, those later diagnosed with PAH or had SBP at least 140 or DBP at least 90 mm Hg at their last clinic visit (stage 2 HTN). The primary outcome was a composite of adverse neonatal outcomes. Univariable and multivariable analyses were performed. RESULTS: 8,778 women were included in the analysis with 1,114 (12.7%) who would have been re-labeled as stage I hypertension by the recent guideline (Group 2). Groups differed on baseline and demographic characteristics (table 1) . After adjusting for these differences, women in Group 2 did not have higher primary composite maternal (aOR 0.86, 95% CI 0.69-1.07) or neonatal (aOR 0.94, 95% CI 0.74-1.18) adverse outcomes, or other outcomes compared with Group 1 (Table 2) . As expected, women in Group 3 had higher odds of developing the composite maternal outcome (aOR 1.35, 95% CI 1.17-1.56) and various adverse maternal outcomes and their infants had higher odds of developing the primary (aOR 1.47, 95% CI 1.26-1.72) and various secondary outcomes, compared with those from Group 1 ( Were included all patients with PPROM prior to 35 weeks with homecare inclusion criteria. Women were considered suitable for outpatient care if there were no uterine contractions, no clinical and biological suspicion of infection, clinical stability after 5-7 days of hospitalization and a cervix dilatation under 3cm. The primary outcome measure was to study length of latency period (delay between PPROM and delivery). Second outcomes measures were maternal and perinatal morbidities and mortalities RESULTS: Among the 395 women included after PPROM, 191 were managed as outpatients and 204 in hospital. In the outpatient group the length of latency period was longer than in the hospital group (39.0 (20.0 ;66.0) versus 21.0 (13.0 ;42.0)) days ; p<0,001). Concerning secondary outcomes, we report none case of intra uterine fetal death in the outpatient group against 2 (0.9%) in the hospital group, and respectively 3 (1.6%) placental abruption versus 4 (2.0%), and 3 (1.6%) cords prolapse versus 1 (0.5%). Clinical chorioamnionitis was observed in 30 (15.7%) in outpatient group versus 41 (20.1%) in outpatient group (p ¼ 0.02). Concerning neonatal outcome, there were less transfer in neonatal intensive care, less respiratory distress syndrome in the outpatient group than in the hospital group ( 29,4% versus 47,5% ; p < 0,001), less neonatal sepsis ( 13,9% versus 22,1% ; p < 0,037), less chronic neonatal lung disease ( 20,2% versus 36,3% ; p ¼0,001), less bronchodysplasia ( 2,7% versus 9,8% ; p¼0,004) and less pulmonary arterial hypertension (4,8% versus 10,3% ; p¼0,04). There were also lets neonatal death in the oupatient group ( 2,1% versus 3,9%) but the difference was not statistically significant. CONCLUSION: Home management seems to be a safe alternative to hospitalization in selected patients with PPROM between 24 and 35 weeks. However, a randomized study would be necessary to confirm those results.
457 Does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity? 
